Latest Market News

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

Nimy Resources has announced a maiden JORC Inferred Resource for high-grade gallium and rare earth elements at its Mons Project in Western Australia, marking a significant step towards becoming a key supplier in critical minerals.

Pilot Energy has made significant strides in Q4 2025 with the launch of a modular data centre joint venture, progress on a hybrid solar and battery project, and advancement of offshore gas exploration partnerships, supported by substantial new financing.

Blue Energy Limited reports steady progress on its Sapphire gas project and awaits key government decisions on additional resource areas, positioning itself strongly in Queensland's evolving energy landscape.

Golden Horse Minerals reports multiple shallow, high-grade gold intersections at Golden Valley and significant deep drilling success at Southern Cross, backed by a $35 million capital raise to fuel 2026 growth.

Vita Resources NL, formerly Bastion Minerals, has advanced its Canadian and Australian projects with new exploration agreements and acquisitions, supported by a recent capital raise. The company is gearing up for significant exploration activities in 2026 under its refreshed corporate identity.

Holista Colltech has reported a positive operating cash flow for the December quarter, driven by disciplined cost management and a successful capital raise, despite softer sales and ongoing legal disputes.

Optiscan Imaging Ltd has made significant strides in clinical studies and regulatory readiness, partnering with Australian Clinical Labs and launching new cancer imaging trials as it prepares for multiple FDA submissions in 2026.

Opthea Limited has streamlined its operations with a NASDAQ delisting and completed a strategic review, positioning itself to advance the OPT-302 treatment for LAM with a robust cash position.

Nagambie Resources and Alkane Resources have entered a binding agreement for a joint venture that could see Alkane invest up to $27.5 million to earn an 80% stake in Nagambie's key mining tenements, leveraging Alkane’s existing processing infrastructure to accelerate production.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Alpha HPA Limited has successfully raised A$225 million through a fully underwritten equity placement, bolstered by strong institutional support, to fund the next phase of its high purity alumina project. This capital injection, combined with existing cash and government funding, positions the company to advance its Stage 2 construction and expand Stage 1 capacity.